Cancer is currently one of the most notorious diseases, with over one million deaths in the
European Union alone in 2022. What makes it truly devastating is its heterogeneity, as each …

Precision oncology seeks to predict the best therapeutic option for individual patients based
on the molecular characteristics of their tumors. To assess the preclinical feasibility of drug …

(1) Background: Inter-tumour heterogeneity is one of cancer's most fundamental features.
Patient stratification based on drug response prediction is hence needed for effective anti …

Motivation Cell lines and patient-derived xenografts (PDXs) have been used extensively to
understand the molecular underpinnings of cancer. While core biological processes are …

Background Methods using cell line microarray and drug sensitivity data to predict patients'
chemotherapy response are appealing, but groups may be reluctant to release details to …

Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer
and are responsible for imparting differential drug responses in cancer patients. Recently …

Background: Predicting and tailoring optimal cancer treatments presents a major challenge.
Methods: A computational model (kinetically tailored treatment, or KITT model) is developed …

Patient-derived xenograft (PDX) models maintain the complex intra-tumoral biology and
heterogeneity of an intact malignancy, as well as the interplay with stromal components and …

The US National Cancer Institute has screened more than 100,000 anticancer compounds
using a panel of 60 diverse human cancer cell lines (NCI-60), which has provided a rich …

The emergence of precision oncology approaches has begun to inform clinical decision-
making in diagnostic, prognostic, and treatment contexts. High-throughput technology has …